At Lonza we always welcome interest and inquiries from the media about our business, services and capabilities. Please use the resources on this page, or contact our media relations team for specific inquiries, and we will connect you to the appropriate business leader or subject matter expert.

18 May 2021
Lonza Launches Next Generation 4D-Nucleofector Cell Transfection Platform with...
Lonza launches next-generation 4D-Nucleofector® Platform, the leading non-viral cell transfection method for a wide variety of cell types – even those traditionally hard to...
23 September 2021
Allarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, a Renal...
Integrated solution for process development and manufacturing of drug substance and drug product will facilitate the advancement of clinical development The agreement meets...
23 July 2021
Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3%...
In H1 2021, Lonza continued its strong performance with 14.7%1 sales growth and 33.3% CORE EBITDA margin, despite headwinds arising from COVID-19Continued focus on growth CAPEX...